National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England

A Contract Award Notice
by THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)

Source
Find a Tender
Type
Framework (Goods)
Duration
1 year (est.)
Value
£1
Sector
HEALTH
Published
28 Apr 2021
Delivery
01 Apr 2021 to 31 Mar 2022 (est.)
Deadline
n/a

Concepts

Location

United Kingdom: ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above.

Geochart for 1 buyers and 93 suppliers

1 buyer

4 suppliers

Description

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Lot Division

1 Atezolizumab - Lot 1

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
2 Bevacizumab (Avastin) - Lot 2

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
3 Bevacizumab (Zirabev) - Lot 3

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
4 Bevacizumab (Aybintio) - Lot 4

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
5 Bleomycin - Lot 5

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
6 Bortezomib - Lot 6

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
7 Carboplatin - Lot 7

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
8 Cetuximab - Lot 8

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
9 Cisplatin - Lot 9

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
10 Cyclophosphamide Syringes - Lot 10

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
11 Cyclophosphamide Bags - Lot 11

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
12 Cytarabine - Lot 12

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
13 Docetaxel - Lot 13

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
14 Doxorubicin - Lot 14

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
15 Epirubicin - Lot 15

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
16 Fludarabine Syringes - Lot 16

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
17 Fludarabine Bags - Lot 17

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
18 Fluorouracil Syringes - Lot 18

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
19 Fluorouracil Bags - Lot 19

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
20 Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
21 Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
22 Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
23 Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
24 Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
25 Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
26 Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
27 Ganciclovir - Lot 27

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
28 Gemcitabine - Lot 28

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
30 Irinotecan - Lot 30

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
31 Methotrexate - Lot 31

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months.
32 Nivolumab - Lot 32

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
33 Obinutuzumab - Lot 33

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
34 Oxaliplatin - Lot 34

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
35 Paclitaxel - Lot 35

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
36 Panitumumab - Lot 36

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
37 Pembrolizumab - Lot 37

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
38 Pemetrexed - Lot 38

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
39 Pertuzumab - Lot 39

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
40 Rituximab (Mabthera) - Lot 40

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
41 Rituximab (Rixathon) - Lot 41

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
42 Rituximab (Truxima) - Lot 42

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
43 Trastuzumab (Herceptin) - Lot 43

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
44 Trastuzumab (Herzuma) - Lot 44

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
45 Trastuzumab (Kanjinti) - Lot 45

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
46 Trastuzumab (Ontruzant) - Lot 46

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
47 Trastuzumab (Trasimera) - Lot 47

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
48 Vinblastine - Lot 48

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
49 Vincristine - Lot 49

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
50 Vinorelbine - Lot 50

The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Award Detail

1 Qualasept (Corsham)
  • Reference: 009177-2021-1
  • Value: £1
2 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-2
  • Value: £1
3 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-3
  • Value: £1
4 Ith Pharma (London)
  • Reference: 009177-2021-4
  • Value: £1
5 Qualasept (Corsham)
  • Reference: 009177-2021-5
  • Value: £1
6 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-6
  • Value: £1
7 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-7
  • Value: £1
8 Ith Pharma (London)
  • Reference: 009177-2021-8
  • Value: £1
9 Qualasept (Corsham)
  • Reference: 009177-2021-9
  • Value: £1
10 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-10
  • Value: £1
11 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-11
  • Value: £1
12 Ith Pharma (London)
  • Reference: 009177-2021-12
  • Value: £1
13 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-13
  • Value: £1
14 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-14
  • Value: £1
15 Ith Pharma (London)
  • Reference: 009177-2021-15
  • Value: £1
16 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-16
  • Value: £1
17 Ith Pharma (London)
  • Reference: 009177-2021-17
  • Value: £1
18 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-18
  • Value: £1
19 Qualasept (Corsham)
  • Reference: 009177-2021-19
  • Value: £1
20 Qualasept (Corsham)
  • Reference: 009177-2021-20
  • Value: £1
21 Ith Pharma (London)
  • Reference: 009177-2021-21
  • Value: £1
22 Ith Pharma (London)
  • Reference: 009177-2021-22
  • Value: £1
23 Ith Pharma (London)
  • Reference: 009177-2021-23
  • Value: £1
24 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-24
  • Value: £1
25 Ith Pharma (London)
  • Reference: 009177-2021-25
  • Value: £1
26 Qualasept (Corsham)
  • Reference: 009177-2021-26
  • Value: £1
27 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-27
  • Value: £1
28 Qualasept (Corsham)
  • Reference: 009177-2021-28
  • Value: £1
29 Qualasept (Corsham)
  • Reference: 009177-2021-29
  • Value: £1
30 Qualasept (Corsham)
  • Reference: 009177-2021-30
  • Value: £1
31 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-31
  • Value: £1
32 Ith Pharma (London)
  • Reference: 009177-2021-32
  • Value: £1
33 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-33
  • Value: £1
34 Qualasept (Corsham)
  • Reference: 009177-2021-34
  • Value: £1
35 Ith Pharma (London)
  • Reference: 009177-2021-35
  • Value: £1
36 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-36
  • Value: £1
37 Ith Pharma (London)
  • Reference: 009177-2021-37
  • Value: £1
38 Qualasept (Corsham)
  • Reference: 009177-2021-38
  • Value: £1
39 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-39
  • Value: £1
40 Qualasept (Corsham)
  • Reference: 009177-2021-40
  • Value: £1
41 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-41
  • Value: £1
42 Qualasept (Corsham)
  • Reference: 009177-2021-42
  • Value: £1
43 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-43
  • Value: £1
44 Qualasept (Corsham)
  • Reference: 009177-2021-44
  • Value: £1
45 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-45
  • Value: £1
46 Qualasept (Corsham)
  • Reference: 009177-2021-46
  • Value: £1
47 Ith Pharma (London)
  • Reference: 009177-2021-47
  • Value: £1
48 Ith Pharma (London)
  • Reference: 009177-2021-48
  • Value: £1
49 Qualasept (Corsham)
  • Reference: 009177-2021-49
  • Value: £1
50 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-50
  • Value: £1
51 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-51
  • Value: £1
52 Ith Pharma (London)
  • Reference: 009177-2021-52
  • Value: £1
53 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-53
  • Value: £1
54 Qualasept (Corsham)
  • Reference: 009177-2021-54
  • Value: £1
55 Ith Pharma (London)
  • Reference: 009177-2021-55
  • Value: £1
56 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-56
  • Value: £1
57 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-57
  • Value: £1
58 Qualasept (Corsham)
  • Reference: 009177-2021-58
  • Value: £1
59 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-59
  • Value: £1
60 Ith Pharma (London)
  • Reference: 009177-2021-60
  • Value: £1
61 Qualasept (Corsham)
  • Reference: 009177-2021-61
  • Value: £1
62 Qualasept (Corsham)
  • Reference: 009177-2021-62
  • Value: £1
63 Qualasept (Corsham)
  • Reference: 009177-2021-63
  • Value: £1
64 Ith Pharma (London)
  • Reference: 009177-2021-64
  • Value: £1
65 Qualasept (Corsham)
  • Reference: 009177-2021-65
  • Value: £1
66 Ith Pharma (London)
  • Reference: 009177-2021-66
  • Value: £1
67 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-67
  • Value: £1
68 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-68
  • Value: £1
69 Qualasept (Corsham)
  • Reference: 009177-2021-69
  • Value: £1
70 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-70
  • Value: £1
71 Ith Pharma (London)
  • Reference: 009177-2021-71
  • Value: £1
72 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-72
  • Value: £1
73 Qualasept (Corsham)
  • Reference: 009177-2021-73
  • Value: £1
74 Qualasept (Corsham)
  • Reference: 009177-2021-74
  • Value: £1
75 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-75
  • Value: £1
76 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-76
  • Value: £1
77 Ith Pharma (London)
  • Reference: 009177-2021-77
  • Value: £1
78 Qualasept (Corsham)
  • Reference: 009177-2021-78
  • Value: £1
79 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-79
  • Value: £1
80 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-80
  • Value: £1
81 Ith Pharma (London)
  • Reference: 009177-2021-81
  • Value: £1
82 Qualasept (Corsham)
  • Reference: 009177-2021-82
  • Value: £1
83 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-83
  • Value: £1
84 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-84
  • Value: £1
85 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-85
  • Value: £1
86 Ith Pharma (London)
  • Reference: 009177-2021-86
  • Value: £1
87 Qualasept (Corsham)
  • Reference: 009177-2021-87
  • Value: £1
88 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-88
  • Value: £1
89 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-89
  • Value: £1
90 Qualasept (Corsham)
  • Reference: 009177-2021-90
  • Value: £1
91 Ith Pharma (London)
  • Reference: 009177-2021-91
  • Value: £1
92 Quantum Aseptic Services (Burnopfield)
  • Reference: 009177-2021-92
  • Value: £1
93 Baxter Healthcare (Newbury)
  • Reference: 009177-2021-93
  • Value: £1

Award Criteria

price _

CPV Codes

  • 33600000 - Pharmaceutical products

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **

Reference

Domains